Ronald de Wit
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
Papers in
- Surgery 164
- Bladder and Urothelial Cancer Treatments 98
- Testicular diseases and treatments 41
- Urinary and Genital Oncology Studies 27
-
- Prostate Cancer Treatment and Research 130
- Co-authors
- Mario A. Eisenberger (35 shared papers)Ian F. Tannock (22 shared papers)Kim N. (5 shared papers)Christine Théodore (10 shared papers)Stéphane Oudard (15 shared papers)Mark Rosenthal (2 shared papers)Nicholas D. James (4 shared papers)A Płużańska (3 shared papers)
- Journals
- Journal of Clinical Oncology (115 papers)Annals of Oncology (41 papers)European Journal of Cancer (30 papers)British Journal of Cancer (20 papers)European Urology (15 papers)
- Partner nations
- NetherlandsUnited StatesFrance
In The Last Decade
Ronald de Wit
367 papers receiving 26.2k citations
Ronald de Wit's Hit Papers
Peers
Comparison fields: 5 of 142
- Pulmonary and Respiratory Medicine 11.1k
- Oncology 7.3k
- Cancer Research 3.1k
- Surgery 8.5k
- Radiology, Nuclear Medicine and Imaging 2.2k
Countries citing papers authored by Ronald de Wit
This map shows the geographic impact of Ronald de Wit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald de Wit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald de Wit more than expected).
Fields of papers citing papers by Ronald de Wit
This network shows the impact of papers produced by Ronald de Wit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald de Wit. The network helps show where Ronald de Wit may publish in the future.
Co-authors
The 25 scholars most cited alongside Ronald de Wit, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 377 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4359 |
| 2 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3351 |
| 3 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Hit paper breakdown → | 2017 | 2413 |
| 4 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 959 |
| 5 | Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study Hit paper breakdown → | 2008 | 825 |
| 6 | The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group Hit paper breakdown → | 2003 | 594 |
| 7 | Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 Hit paper breakdown → | 2011 | 536 |
| 8 | Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 386 |
| 9 | Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study Hit paper breakdown → | 2021 | 343 |
| 10 | Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 Hit paper breakdown → | 2012 | 327 |
| 11 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up Hit paper breakdown → | 2019 | 318 |
| 12 | 2007 | 314 | |
| 13 | 1997 | 303 | |
| 14 | 2007 | 282 | |
| 15 | 2002 | 276 | |
| 16 | 2005 | 269 | |
| 17 | 2006 | 245 | |
| 18 | 2001 | 221 | |
| 19 | 1997 | 221 | |
| 20 | 2003 | 216 |
About Ronald de Wit
Ronald de Wit is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 377 papers that have together received 26.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (130 papers), Bladder and Urothelial Cancer Treatments (98 papers), Cancer Immunotherapy and Biomarkers (62 papers), Testicular diseases and treatments (41 papers), Radiopharmaceutical Chemistry and Applications (40 papers), Cancer Treatment and Pharmacology (40 papers), Urinary and Genital Oncology Studies (27 papers) and Multiple and Secondary Primary Cancers (19 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (11.1k citations), Oncology (7.3k citations), Cancer Research (3.1k citations), Surgery (8.5k citations) and Radiology, Nuclear Medicine and Imaging (2.2k citations). Ronald de Wit has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Mario A. Eisenberger, Ian F. Tannock, Kim N., Christine Théodore, Stéphane Oudard, Mark Rosenthal, Nicholas D. James, A Płużańska, Cora N. Sternberg and Joaquim Bellmunt. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.